NCT06887127View on ClinicalTrials.gov

A Long-term Extension Clinical Study of TLL-018 in Patients With Rheumatoid Arthritis

PHASE3RecruitingINTERVENTIONAL
Enrollment

350

Participants

Timeline

Start Date

March 10, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2027

Conditions
Rheumatoid Arthritis
Interventions
DRUG

TLL-018

TLL-018 20 mg BID for 78 weeks

Trial Locations (1)

100022

RECRUITING

Peking Union Hospital, Chinese Academy of Medical Sciences, Beijing

Sponsors
All Listed Sponsors
lead

Hangzhou Highlightll Pharmaceutical Co., Ltd

INDUSTRY